In the past week, GERN stock has gone down by -8.83%, with a monthly decline of -24.15% and a quarterly plunge of -30.70%. The volatility ratio for the week is 6.34%, and the volatility levels for the last 30 days are 5.39% for Geron Corp The simple moving average for the last 20 days is -13.11% for GERN stock, with a simple moving average of -29.62% for the last 200 days.
Is It Worth Investing in Geron Corp (NASDAQ: GERN) Right Now?
The stock has a 36-month beta value of 0.55. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GERN is 564.66M, and at present, short sellers hold a 11.52% of that float. On January 20, 2025, the average trading volume of GERN was 10.44M shares.
GERN) stock’s latest price update
Geron Corp (NASDAQ: GERN)’s stock price has plunge by -1.03relation to previous closing price of 2.92. Nevertheless, the company has seen a -8.83% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-16 that Geron Corporation’s RYTELO received FDA approval for Low-Risk Myelodysplastic Syndrome and is awaiting European Medicines Agency approval as well, which might help to boost sales. Geron reported $28.2 million in the first full quarter of sales of RYTELO, with projections of $45-$46 million set for Q4 2024. Geron is conducting a Phase 3 study for RYTELO targeting JAK inhibitor relapsed/refractory Myelofibrosis patients, with interim results expected by early 2026 and final results early 2027.
Analysts’ Opinion of GERN
Many brokerage firms have already submitted their reports for GERN stocks, with H.C. Wainwright repeating the rating for GERN by listing it as a “Buy.” The predicted price for GERN in the upcoming period, according to H.C. Wainwright is $8 based on the research report published on November 05, 2024 of the previous year 2024.
Leerink Partners gave a rating of “Outperform” to GERN, setting the target price at $7 in the report published on September 09th of the previous year.
GERN Trading at -22.46% from the 50-Day Moving Average
After a stumble in the market that brought GERN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.88% of loss for the given period.
Volatility was left at 5.39%, however, over the last 30 days, the volatility rate increased by 6.34%, as shares sank -26.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.00% lower at present.
During the last 5 trading sessions, GERN fell by -8.83%, which changed the moving average for the period of 200-days by -6.77% in comparison to the 20-day moving average, which settled at $3.33. In addition, Geron Corp saw -18.36% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GERN starting from GRETHLEIN ANDREW J, who sale 674,348 shares at the price of $4.56 back on Jul 08 ’24. After this action, GRETHLEIN ANDREW J now owns 0 shares of Geron Corp, valued at $3,073,004 using the latest closing price.
Feller Faye, the EVP, Chief Medical Officer of Geron Corp, sale 287,900 shares at $4.63 during a trade that took place back on Jun 10 ’24, which means that Feller Faye is holding 0 shares at $1,334,129 based on the most recent closing price.
Stock Fundamentals for GERN
Current profitability levels for the company are sitting at:
- -7.05 for the present operating margin
- 0.97 for the gross margin
The net margin for Geron Corp stands at -6.82. The total capital return value is set at -0.79. Equity return is now at value -69.03, with -46.90 for asset returns.
Based on Geron Corp (GERN), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -13.69. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -17.16.
Currently, EBITDA for the company is -174.78 million with net debt to EBITDA at 0.24. When we switch over and look at the enterprise to sales, we see a ratio of 57.75. The receivables turnover for the company is 1.05for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.89.
Conclusion
To sum up, Geron Corp (GERN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
